Enhanced Epidermal Antigen Specific Immunotherapy Trial -1

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 29, 2016

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2019

Conditions

Type 1 Diabetes

Interventions

DRUG

C19-A3 GNP

C19A3 GNP intradermal microinjectable solution of human C19A3 proinsulin peptide coupled to gold.

Trial Locations (1)

Cardiff and Vale University Health Board, Cardiff

All Listed Sponsors

lead

Cardiff University

OTHER

NCT02837094 - Enhanced Epidermal Antigen Specific Immunotherapy Trial -1 | Biotech Hunter | Biotech Hunter